Amgen reported Phase 3 findings at ESMO showing that an Imdelltra (tarlatamab) plus AstraZeneca’s Imfinzi (durvalumab) regimen cut the risk of death by 58% versus Imfinzi alone in a first-line maintenance setting for certain small cell lung cancer patients. The benefit comes with the trial meeting its key benchmark in the maintenance population. The readout strengthens a growing field of targeted bispecific and checkpoint combinations in small cell disease, where durability remains a central bar for new regimens. Amgen’s combination strategy also signals an attempt to broaden utility beyond single-agent approaches by pairing mechanism-focused activity with immune checkpoint maintenance. For the broader biotech ecosystem, the dataset adds competitive pressure in front-line SCLC and may influence how future trials select maintenance endpoints and biomarker-enriched subgroups.